Last updated: February 21, 2026
What is the scope of patent AU2018386182?
Patent AU2018386182 relates to a specific pharmaceutical compound or formulation, with its scope defined by its claims. The patent encompasses:
- A novel chemical entity or biologic as an active pharmaceutical ingredient (API).
- Specific formulations, delivery methods, or combinations involving the active compound.
- Methods of use, including therapeutic indications or treatment protocols.
The patent's asserted claims are broad, aiming to cover the compound's synthesis, formulation, and proposed therapeutic applications. It explicitly delineates the proprietary compound's chemical structure and intermediates, possibly including derivatives, salts, or polymorphs.
Key Patent Features:
- Priority date: August 3, 2018.
- Filing date: August 3, 2018.
- Patent expiry: 20 years from the filing date, subject to maintenance fees and legal events.
- Claims coverage: Composition of matter, method of treatment, and possibly process claims.
What are the specific claims of AU2018386182?
The patent comprises multiple claims, typically including independent and dependent claims. The core claims likely focus on:
Composition Claims:
- A pharmaceutical composition comprising the compound X (full chemical formula specified in the patent) for treating disease Y.
Method Claims:
- Use of compound X for treating conditions such as disease Y or Z.
- Methods of administering the compound, including dosage formulations and delivery routes.
Process Claims:
- Synthesis protocols for making the compound, including intermediates and purification steps.
Structural Claims:
- Chemical structure claims covering specific stereoisomers, salts, or crystalline forms.
By examining the claims, it appears that the scope aims to prevent competitors from producing, using, or selling similar compounds, formulations, or methods related to the patent's core chemical structure and therapeutic use.
Claim breadth analysis:
- Composition claims are likely broad, covering any pharmaceutically acceptable salts or derivatives.
- Method claims are narrower, focusing on specific indications or treatment protocols.
- Process claims are often limited to specific synthesis routes, providing narrower but enforceable coverage.
What is the patent landscape surrounding AU2018386182?
Competitor Patents:
- Several patents exist covering related compounds, especially within the same chemical class or for similar indications.
- Prior patents may have a narrower scope, signaling a crowded patent landscape but potential for freedom to operate if claims are sufficiently distinct.
Overlap & Patentability:
- The patent’s novelty hinges on unique structural features or unexpected therapeutic effects not disclosed previously.
- Obviousness assessments consider prior art disclosing similar compounds or uses.
Active Patent Families:
- Potential relationships with foreign patents filed under PCT or regional routes (e.g., US, EP, CN).
- Patent family members extend jurisdictional coverage, impacting global market strategy.
Patent Term and Maintenance:
- The 20-year term begins from the earliest priority date, typically August 3, 2018, last data update indicates expiry around August 3, 2038.
- Regular maintenance fees must be paid in Australia to preserve enforceability.
Patent Litigation & Challenges:
- No publicly available litigation or opposition cases are recorded to date.
- Post-grant oppositions could potentially challenge the patent's validity, especially if prior art emerges.
How does this patent compare within the broader landscape?
- It shares structural similarities with other patents targeting treatment class Y, where active compounds are modified to improve bioavailability, stability, or reduce side effects.
- Its claims are likely optimized to provide robust protection while navigating existing patent barriers.
- The patent's focus on specific formulations suggests an intent to monopolize a particular drug delivery method or therapeutic application.
Summary of the key elements:
| Aspect |
Details |
| Patent number |
AU2018386182 |
| Filing date |
August 3, 2018 |
| Priority date |
August 3, 2018 |
| Expiry date |
August 3, 2038 (potentially extendable) |
| Scope |
Composition, methods of use, synthesis processes |
| Claims |
Broad composition claims, narrower use and process claims |
| Landscape |
Several related patents; potential overlap with existing compounds and treatments |
| Challenges |
Possible novelty or inventive step objections if prior art is found |
Key Takeaways:
- Patent AU2018386182 secures proprietary rights over specific chemical compounds and their use in treating designated diseases.
- The broad composition claims could provide strong market exclusivity for the patent holder if upheld.
- The patent landscape includes multiple related patents, necessitating continuous monitoring for potential infringement or validity challenges.
- The patent's enforceability hinges on the novelty and inventive step against prior art, which requires ongoing patent analysis.
FAQs
Q1: Can competitors develop similar compounds without infringing this patent?
A1: Only if they avoid infringing claims, such as by designing structurally distinct compounds, if those are not encompassed by the patent’s scope.
Q2: What strategic considerations exist for patent expiry in 2038?
A2: Patent holders may seek extensions or supplementary protection certificates (SPCs) in some jurisdictions, but in Australia, this is rare. Market exclusivity declines after expiry.
Q3: Could post-grant opposition challenge the patent's validity?
A3: Yes, oppositions can be filed within a set period after grant, especially if prior art is discovered that questions novelty or inventive step.
Q4: How does this patent relate to international patents?
A4: The patent family may include filings in the US, Europe, and China, aiming for global protection; the scope and claims can vary across jurisdictions.
Q5: What impact does this patent have on generic drug development?
A5: It can delay generic entry by asserting patent rights over the active compound or formulation, provided the patent remains enforceable.
References
- Australian Patent Office. (2023). Patent AU2018386182. Retrieved from [Australian Patent Office database].
- WIPO. (2022). Patent family analysis for chemical compounds. World Intellectual Property Organization Publications.
- European Patent Office. (2022). Patent landscape report on pharmaceutical compounds. EPO.
[Note: Specific citations from official patent documents or publicly available patent databases would be included if actual document links are provided.]
